Aion Therapeutic Inc.
ANTCF
$0.012
-$0.003-20.00%
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.45% | -25.03% | -45.26% | -41.85% | -56.05% |
| Depreciation & Amortization | -21.68% | -81.51% | -76.72% | -74.95% | -79.39% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.76% | -49.35% | -64.32% | -65.93% | -59.68% |
| Operating Income | 29.48% | 49.35% | 64.32% | 65.93% | 59.68% |
| Income Before Tax | -25.93% | 19.00% | 45.62% | 94.72% | 84.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.93% | 19.00% | 45.62% | 94.72% | 84.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.93% | 19.00% | 45.62% | 94.72% | 84.78% |
| EBIT | 29.48% | 49.35% | 64.32% | 65.93% | 59.68% |
| EBITDA | 67.86% | 78.43% | 74.39% | 65.68% | 59.07% |
| EPS Basic | 0.00% | 26.14% | 49.61% | 95.83% | 86.90% |
| Normalized Basic EPS | 51.02% | 52.46% | 65.88% | 66.34% | 63.16% |
| EPS Diluted | 7.14% | 31.63% | 60.00% | 93.02% | 86.62% |
| Normalized Diluted EPS | 48.94% | 50.85% | 65.06% | 68.32% | 64.66% |
| Average Basic Shares Outstanding | 41.76% | 13.78% | 7.32% | 4.65% | 8.31% |
| Average Diluted Shares Outstanding | 33.83% | 7.35% | 1.20% | 10.80% | 14.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
